<p>Champions Oncology（CSBR）召开了第二季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>享受 TipRanks Premium 50% 折扣，安心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Champions Oncology 最近的财报电话会议描绘了强劲的财务健康状况，年同比收入增长显著，毛利率提升。公司正在对放射性标记和数据平台进行战略投资，预计将推动长期增长。尽管这些积极指标存在，但增加的运营费用和现金流挑战被强调为关注领域。总体而言，会议的情绪表明对 Champions Oncology 的前景持乐观态度。</p>
<h2>年同比收入增长</h2>
<p>Champions Oncology 报告第二季度收入为 1500 万美元，比去年 1350 万美元增长 11%。这一增长主要得益于已预定工作的转化率提升，展示了公司利用市场机会的能力。</p>
<h2>毛利率改善</h2>
<p>公司实现了 52% 的毛利率，较去年 45% 上升。这一改善归因于运营效率和稳定的销售成本，反映了 Champions Oncology 的有效管理策略。</p>
<h2>放射性标记和放射药物的成功</h2>
<p>Champions Oncology 在放射性标记和放射药物支持工作流程方面持续表现出色，使公司在肿瘤药物开发市场中独树一帜。这一成功凸显了其竞争优势和未来增长的潜力。</p>
<h2>对数据平台的投资</h2>
<p>公司正在积极投资于其数据平台，以增强功能并更好地支持制药合作伙伴。这一战略举措引起了客户的极大兴趣，表明未来收入来源的良好前景。</p>
<h2>正向调整后 EBITDA</h2>
<p>Champions Oncology 正在朝着实现全年正向调整后 EBITDA 的目标迈进，与其 2026 财年的核心财务目标一致。这一里程碑反映了公司对财务稳定和增长的承诺。</p>
<h2>运营费用增加</h2>
<p>与去年相比，运营费用增加了 200 万美元，主要由于对数据平台和其他战略优先事项的投资。尽管这一增长显著，但与公司的增长战略相符。</p>
<h2>现金流挑战</h2>
<p>公司面临现金流挑战，运营活动净现金使用额达到 190 万美元。这主要是由于递延收入的减少，突显了需要关注的领域。</p>
<h2>前瞻性指导</h2>
<p>首席执行官 Robert Brainin 提供了未来几个季度的指导，强调继续实现年同比收入增长和保持全年正向调整后 EBITDA 的目标。公司拥有 850 万美元现金且无债务，专注于利用其放射性标记能力和扩展数据平台以推动长期增长。管理层对未来表现持乐观态度，得益于市场条件的改善和客户参与度的提升。</p>
<p>总之，Champions Oncology 的财报电话会议反映了积极的财务轨迹，得益于战略投资和运营效率。尽管存在运营费用增加和现金流问题等挑战，但公司的强劲收入增长和独特的市场定位表明前景乐观。投资者和利益相关者可以对 Champions Oncology 的未来表现保持乐观。</p>

CSBR

<p>Champions Oncology 公布了强劲的第二季度财务业绩，收入增长 11%，达到 1500 万美元，毛利率提升至 52%。在放射性标记和数据平台方面的战略投资预计将推动长期增长。尽管运营费用增加和现金流面临挑战，公司仍致力于持续的收入增长和正向调整后的息税折旧摊销前利润（EBITDA）。管理层手握 850 万美元现金且无债务，对未来表现保持乐观，得益于市场条件的改善和客户参与度的提升</p>

<p>Champions Oncology ((CSBR)) has held its Q2 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Champions Oncology（CSBR）召开了第二季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，安心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Champions Oncology’s recent earnings call painted a picture of robust financial health, with notable year-over-year revenue growth and enhanced gross margins. The company is making strategic investments in radiolabeling and its data platform, which are anticipated to fuel long-term growth. Despite these positive indicators, increased operating expenses and cash flow challenges were highlighted as areas of concern. Overall, the sentiment from the call suggests a favorable outlook for Champions Oncology.</p>
<div class="lb-trans"><p>Champions Oncology 最近的财报电话会议描绘了强劲的财务健康状况，年同比收入增长显著，毛利率提升。公司正在对放射性标记和数据平台进行战略投资，预计将推动长期增长。尽管这些积极指标存在，但增加的运营费用和现金流挑战被强调为关注领域。总体而言，会议的情绪表明对 Champions Oncology 的前景持乐观态度。</p>
</div><h2>Year-over-Year Revenue Growth</h2>
<div class="lb-trans"><h2>年同比收入增长</h2>
</div><p>Champions Oncology reported a revenue of $15 million for the second quarter, marking an 11% increase from the previous year’s $13.5 million. This growth was primarily driven by improved conversion of booked work, showcasing the company’s ability to capitalize on its market opportunities.</p>
<div class="lb-trans"><p>Champions Oncology 报告第二季度收入为 1500 万美元，比去年 1350 万美元增长 11%。这一增长主要得益于已预定工作的转化率提升，展示了公司利用市场机会的能力。</p>
</div><h2>Improved Gross Margin</h2>
<div class="lb-trans"><h2>毛利率改善</h2>
</div><p>The company achieved a gross margin of 52%, up from 45% last year. This improvement was attributed to operational efficiencies and a stable cost of sales, reflecting Champions Oncology’s effective management strategies.</p>
<div class="lb-trans"><p>公司实现了 52% 的毛利率，较去年 45% 上升。这一改善归因于运营效率和稳定的销售成本，反映了 Champions Oncology 的有效管理策略。</p>
</div><h2>Radiolabeling and Radiopharmaceutical Success</h2>
<div class="lb-trans"><h2>放射性标记和放射药物的成功</h2>
</div><p>Champions Oncology continues to excel in radiolabeling and radiopharmaceutical support workflows, which positions the company uniquely within the oncology drug development market. This success underscores its competitive edge and potential for future growth.</p>
<div class="lb-trans"><p>Champions Oncology 在放射性标记和放射药物支持工作流程方面持续表现出色，使公司在肿瘤药物开发市场中独树一帜。这一成功凸显了其竞争优势和未来增长的潜力。</p>
</div><h2>Investment in Data Platform</h2>
<div class="lb-trans"><h2>对数据平台的投资</h2>
</div><p>The company is actively investing in its data platform to enhance functionality and better support pharmaceutical partners. This strategic move has garnered significant customer interest, indicating a promising avenue for future revenue streams.</p>
<div class="lb-trans"><p>公司正在积极投资于其数据平台，以增强功能并更好地支持制药合作伙伴。这一战略举措引起了客户的极大兴趣，表明未来收入来源的良好前景。</p>
</div><h2>Positive Adjusted EBITDA</h2>
<div class="lb-trans"><h2>正向调整后 EBITDA</h2>
</div><p>Champions Oncology is on track to achieve a full-year positive adjusted EBITDA, aligning with its core financial goals for fiscal 2026. This milestone reflects the company’s commitment to financial stability and growth.</p>
<div class="lb-trans"><p>Champions Oncology 正在朝着实现全年正向调整后 EBITDA 的目标迈进，与其 2026 财年的核心财务目标一致。这一里程碑反映了公司对财务稳定和增长的承诺。</p>
</div><h2>Increased Operating Expenses</h2>
<div class="lb-trans"><h2>运营费用增加</h2>
</div><p>Operating expenses rose by $2 million compared to last year, mainly due to investments in the data platform and other strategic priorities. While this increase is notable, it aligns with the company’s growth strategy.</p>
<div class="lb-trans"><p>与去年相比，运营费用增加了 200 万美元，主要由于对数据平台和其他战略优先事项的投资。尽管这一增长显著，但与公司的增长战略相符。</p>
</div><h2>Cash Flow Challenges</h2>
<div class="lb-trans"><h2>现金流挑战</h2>
</div><p>The company faced cash flow challenges, with net cash used in operating activities amounting to $1.9 million. This was primarily driven by a decrease in deferred revenue, highlighting an area that requires attention.</p>
<div class="lb-trans"><p>公司面临现金流挑战，运营活动净现金使用额达到 190 万美元。这主要是由于递延收入的减少，突显了需要关注的领域。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>CEO Robert Brainin provided guidance for the upcoming quarters, emphasizing the aim for continued year-on-year revenue growth and maintaining positive adjusted EBITDA for the full year. With $8.5 million in cash and no debt, the company is focused on leveraging its radiolabeling capabilities and expanding its data platform to drive long-term growth. Management remains optimistic about future performance, supported by improving market conditions and increasing customer engagement.</p>
<div class="lb-trans"><p>首席执行官 Robert Brainin 提供了未来几个季度的指导，强调继续实现年同比收入增长和保持全年正向调整后 EBITDA 的目标。公司拥有 850 万美元现金且无债务，专注于利用其放射性标记能力和扩展数据平台以推动长期增长。管理层对未来表现持乐观态度，得益于市场条件的改善和客户参与度的提升。</p>
</div><p>In summary, Champions Oncology’s earnings call reflects a positive financial trajectory, driven by strategic investments and operational efficiencies. While challenges such as increased operating expenses and cash flow issues exist, the company’s strong revenue growth and unique market positioning suggest a promising outlook. Investors and stakeholders can remain optimistic about Champions Oncology’s future performance.</p>
<div class="lb-trans"><p>总之，Champions Oncology 的财报电话会议反映了积极的财务轨迹，得益于战略投资和运营效率。尽管存在运营费用增加和现金流问题等挑战，但公司的强劲收入增长和独特的市场定位表明前景乐观。投资者和利益相关者可以对 Champions Oncology 的未来表现保持乐观。</p>
</div>

Champions Oncology 在战略投资的推动下报告了强劲的增长